Mar 22, 2023

Selpercatinib is included as a new drug in ProTarget

We are pleased to announce that Retsevmo (selpercatinib) is now available in ProTarget. Patients with a confirmed variant-drug match to selpercatinib may be eligible to inclusion in this study arm.

Selpercatinib is a RET inhibitor belonging to the class of cancer medicines called tyrosine kinase inhibitors. In patients with RET-gene fusions or mutations, abnormal RET-protein expression may lead to uncontrolled cell growth and thereby drive cancer development and tumor growth. By inhibiting RET, selpercatinib may reduce the growth and spread of the cancer cells (1).

Patients eligible for inclusion in the selpercatinib-arm have a RET-mutated or RET-fusion-positive tumor and a histologic tumor type outside the labelled indication. Furthermore, patients must meet all general and drug-specific inclusion and exclusion criteria as described in the protocol.

All potential candidates for selpercatinib must be evaluated and confirmed at the Danish National Molecular Tumor Board before inclusion (2). Selpercatinib is supplied by Eli Lilly.


  1. EMA – Retsevmo (selpercatinib)
  2. The ProTarget protocol